The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia

The Impact of SKP2 Gene Expression in Chronic Myeloid Leukemia

Introduction: The prognosis of chronic myeloid leukemia (CML) patients has been dramatically improved with the introduction of imatinib (IM), the first tyrosine kinase inhibitor (TKI). TKI resistance is a serious problem in IM-based therapy. The human S-phase kinase-associated protein 2 (<i>SK...

Full description

Bibliographic Details
Main Authors: Hossam Hodeib, Dina Abd EL Hai, Mohamed A. Tawfik, Alzahraa A. Allam, Ahmed F. Selim, Mohamed E. Sarhan, Amal Selim, Nesreen M. Sabry, Wael Mansour, Amira Youssef
Format: Article
Language:English
Published: MDPI AG 2022-05-01
Series:Genes
Subjects:
<i>SKP2</i> gene expression
imatinib
treatment response
chronic myeloid leukemia
Online Access:https://www.mdpi.com/2073-4425/13/6/948

Internet

https://www.mdpi.com/2073-4425/13/6/948

Similar Items